Clinical trial
Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
NCT00310661 · Centre for Addiction and Mental Health, Other · Terminated
Key facts
| NCT number | NCT00310661 |
|---|---|
| Title | Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia |
| Official title | A Dual-centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine the Effects of Various Adjunctive Doses of Sarizotan in the Treatment of Patients With Neuroleptic-induced Tardive Dyskinesia |
| Lead sponsor | Centre for Addiction and Mental Health, Other |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Neuroleptic-induced Tardive Dyskinesia |
| Intervention type | Drug, Other |
| Interventions | Sarizotan, Placebo |
| Enrollment | 60 |
| Start date | Dec 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Apr 4, 2006 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada, India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: